title: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
abstract: BACKGROUND
  A randomized, multicenter phase II study evaluating oxaliplatin alone (OXA) and oxaliplatin-5-fluorouracil combination (OXFU) in advanced hormone-refractory prostate cancer (HRPC) patients.
  
  
  METHODS
  Metastatic, pathologically proven prostate carcinoma patients, progressing despite anti-androgen therapy, received intravenous OXA (130 mg/m(2 )over 2 h), alone or with 5-FU (1000 mg/m(2)/day, continuous intravenous infusion, days 1-4), every 3 weeks. OXA patients could receive OXFU after treatment failure.
  
  
  RESULTS
  Fifty-four patients (26 OXA, 28 OXFU) from nine centers received 269 treatment cycles (106 OXA, 163 OXFU; median 3.5 OXA or 5 OXFU cycles per patient; range 1-10 or 1-14, respectively). Patient characteristics were similar in both arms. Three partial responses (PR) occurred in 21 evaluable OXA patients [14%; 95% confidence interval (CI) 1% to 30%], and in five of 26 evaluable OXFU patients (19%; 95% CI 7% to 39%). Clinical benefit response (pain, performance status and weight changes) was assessed in 20 OXA and 22 OXFU symptomatic patients, with more responders in the OXFU arm (39% compared with 12%). Median time to progression in the OXA and OXFU arms was 2.6 and 3.4 months, and median overall survival was 9.4 and 11.4 months, respectively. Hematotoxicity was common, but mostly mild to moderate. Neutropenia was more common in OXFU than OXA patients. After oxaliplatin failure, 12 patients received 46 cycles of OXFU and one of 11 evaluable patients had a PR.
  
  
  CONCLUSIONS
  The objective response rate, palliation benefit, survival and manageable toxicity obtained in this heavily pretreated HRPC population with OXFU merit further study.
authors.affiliation: Leon Berard, Lyon, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
authors.forename: X
authors.initials: X
authors.lastname: Muracciole
authors.forename: N
authors.initials: N
authors.lastname: Mottet
authors.forename: M
authors.initials: M
authors.lastname: Ould Kaci
authors.forename: J M
authors.initials: JM
authors.lastname: Vannetzel
authors.forename: N
authors.initials: N
authors.lastname: Albin
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: J-M
authors.initials: JM
authors.lastname: Rodier
authors.forename: J-L
authors.initials: JL
authors.lastname: Misset
authors.forename: S
authors.initials: S
authors.lastname: Mackenzie
authors.forename: E
authors.initials: E
authors.lastname: Cvitkovic
authors.forename: G
authors.initials: G
authors.lastname: Benoit
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011725:Pyridines / Q000008:administration & dosage*; D018570:Risk Assessment; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009944:Organoplatinum Compounds; D011725:Pyridines; C431073:oxiplatin; D017430:Prostate-Specific Antigen; D005472:Fluorouracil